Breaking News

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

Genius AI Detection Receives FDA Clearance – New Deep Learning-based Software Designed to Help Radiologists Detect Subtle Potential Cancers in Breast Tomosynthesis Images

This new technology, represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius® 3D Mammography™ exam.

Passio Pump Drainage System Granted 510(k) for Additional Indication for Home Use

The Passio Pump Drainage System consists of the Passio Catheter, a Handheld Control Unit (pump) and a Disposable Collection Kit, which includes a redressing kit, for drainage of recurrent and symptomatic pleural effusion.

Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business

Boston Scientific notes SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases.

ORTHO Optix Reader Receives CE Mark and Available in Countries That Accept the CE Mark

"The ORTHO Optix Reader allows transfusion medicine labs with smaller testing volumes the same high-quality, consistent results demonstrated from the award-winning, fully automated ORTHO VISION Analyzer," said Bob Stowers, Ortho's head of transfusion medicine product portfolio.

Inscopix Announces Collaboration With Bruker for Advanced Analysis of Brain Circuits by Combining Miniature Microscopes With Multiphoton Microscopy

July 10, 2020

Inscopix today announced a collaboration with Bruker Corporation (NASDAQ: BRKR) for its new Multimodal Image Registration and Analysis (MIRA) platform.

Inscopix notes the platform and the collaboration will empower brain researchers to catalyze a more precise and comprehensive mechanistic understanding of the brain by seamlessly integrating one-photon imaging of neuronal activity using Inscopix’s miniature microscope-based nVistaTM and nVokeTM systems, with high-resolution and multi-color imaging of diverse cell-types and pathologies in the brain via Bruker’s Ultima multiphoton microscopes.

“We are very excited to announce the launch of the MIRA platform and the collaboration with Bruker, a leader in multiphoton imaging-based applications for neuroscience,” said Kunal Ghosh, Ph.D., CEO and founder of Inscopix. “This partnership with Bruker is a key part of our strategy to work with partners in the neuroscience imaging industry to help researchers record, align, register and correlate changes in neural activity in a defined population of neurons with changes in other brain cell-types and pathologies.”

“Inscopix’s MIRA platform is an important innovation that will, when used in conjunction with our Ultima multiphoton microscopy, combine the many advantages of one-photon and multiphoton imaging, while overcoming previous technological limitations, for a richer and more sophisticated understanding of the brain,” added Xiaomei Li, Ph.D., VP, and GM of Bruker’s Fluorescence Microscopy Business. “We are always seeking out important collaborations with technological leaders, such as Inscopix, to help make functional brain imaging more routine and widespread in the neuroscience research community.”

The MIRA platform is designed such that researchers can first image large-scale brain activity at single-cell resolution in freely-behaving animal subjects, an important benefit of Inscopix. Then, researchers can image the same field-of-view in the brain with multiphoton and confocal microscopes at higher resolution and at multiple wavelengths, an important advantage of Bruker, but which requires animal immobilization. The MIRA platform thus allows researchers to gain greater insights from cells of interest through dual-color imaging and the ability to compare calcium activity between freely-behaving and head-fixed conditions by providing a solution for co-registering cells from both modalities.

The companies will be co-marketing the Inscopix MIRA platform with Bruker’s multiphoton microscopes. The combined solution includes an adapter to integrate Inscopix miniscope data from freely-moving animals with multicolor laser scanning microscope data from the head-fixed animals, along with an Inscopix-developed software solution to streamline co-registering of images obtained from both modalities.

 

Latest Posts

1st Patients Enrolled in STEM Trial for `Treatment of Chronic Subdural Hematoma

This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a common disease affecting primarily older adults.

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

Genius AI Detection Receives FDA Clearance – New Deep Learning-based Software Designed to Help Radiologists Detect Subtle Potential Cancers in Breast Tomosynthesis Images

This new technology, represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius® 3D Mammography™ exam.

Don't Miss

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.